Study wrapper · #662
[Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice].
Editor's note
This preclinical study examined Selank's antidepressant-like effects across two depression models: inherited-type symptoms in WAG/Rij rats and situation-provoked symptoms in BALB/c mice, with outbred Wistar rats as controls. Researchers reported that high-dose Selank (1000-2000 microg/kg), given repeatedly, countered depression-like signs in WAG/Rij rats (immobility in forced swimming, reduced sucrose preference/anhedonia), while low-dose Selank (100-300 microg/kg) as a single injection reduced immobility in BALB/c mice; Selank did not affect general activity or anxiety in WAG/Rij rats or behavior in control Wistar rats. The authors argue for an antidepressant component in Selank's profile and promote the WAG/Rij model. For Selank, usually framed as anxiolytic/nootropic, this adds an antidepressant-like dimension. Weigh it as behavioral rodent data with dose- and model-dependent, sometimes narrow effects. These are preclinical findings; human data are needed before clinical conclusions can be drawn.
Plain-language abstract
Selank is usually studied for anxiety and memory, but this study asked whether it also has antidepressant-like effects in animals. Researchers used two models: rats (WAG/Rij) that show depression-like behavior for genetic reasons, and mice (BALB/c) made to show depression-like behavior by their situation. Ordinary Wistar rats served as a comparison. In the genetically prone rats, high, repeated doses of Selank reduced depression-like signs, such as giving up sooner in a swim test and losing interest in sugar water (a sign of reduced pleasure). In the mice, a single low dose reduced 'giving-up' behavior, but higher or repeated doses did not. Selank did not change general activity or anxiety in the prone rats, or behavior in the ordinary rats. This was an animal study using behavior tests, with effects that depended on dose and model. It suggests Selank may have an antidepressant-like component, but that is early animal evidence, not a finding about depression in people.